Grade D · no indexed studies3 peptides · 89 studies
GLP-1 metabolic framework (Semaglutide / Tirzepatide)
GLP-1 / GIP-GLP-1 framework reflecting some of the densest human data in the library.
This is a description, not a protocol to follow
Everything below is a summary of what people report doing and what the literature contains. Nothing here is medical advice.
What the evidence actually supports
Supported in animals
Animal-model studies indexed · 5
Cell and in-vitro studies indexed · 2
Reviews and uncategorised studies · 34
Not established
Any effect in humans · 48 human studies indexed
Any benefit from combining them · no combination study in our index
Human dose, route or duration · no PK study indexed
Protocol details
The combination of Semaglutide and Tirzepatide has not been studied together in published research. However, individual studies on each compound provide insights into their effects and potential applications.
Tirzepatide has been associated with significant weight loss in various human studies. One observational study reported a mean weight loss of 19.9% over 12 months, indicating high treatment persistence in a real-world setting [1]. Another study found that 83.1% of women achieved at least a 10% weight loss using Tirzepatide in a digital care model, suggesting its effectiveness in obesity management [2]. Additionally, Tirzepatide was linked to lower incidences of cardiovascular events compared to Semaglutide in patients with type 2 diabetes [5].
Semaglutide has also been evaluated in several studies, although specific weight loss outcomes were not detailed in all of them. A review highlighted the need for pediatric trials to assess the safety and efficacy of weight-loss medications like Semaglutide [4]. Furthermore, a meta-analysis suggested no conclusive evidence linking Semaglutide to increased suicidality, although the findings were imprecise [14].
Overall, while both Semaglutide and Tirzepatide have shown promise in weight management and other health outcomes, the lack of studies examining their combined effects means that the specific benefits or interactions of this protocol remain unclear.
Sources
[1] 12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study. — Obesity pillars, 2026 https://doi.org/10.1016/j.obpill.2026.100344
[2] Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women. — Nature medicine, 2026 https://pubmed.ncbi.nlm.nih.gov/42888249/
[4] The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications. — Journal of diabetes and metabolic disorders, 2026 https://doi.org/10.1007/s40200-026-02110-3
[5] Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes. — Journal of diabetes and metabolic disorders, 2026 https://doi.org/10.1007/s40200-026-02087-z
[14] Semaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trials — 2026 https://doi.org/10.21203/rs.3.rs-10976576/v1
Research & studies for this protocol
89 rows · showing 24Newest first
| Study | Compound | Source | Year |
|---|---|---|---|
| This study evaluated the 12-month outcomes of tirzepatide in 249 adults with overweight or obesity under individualized dosing conditions. The mean weight loss was reported as 19.9 ± 8.6% at 12 months, with 68.3% of patients remaining on treatment. The study highlights treatment persistence and predictors of response but does not establish long-term weight maintenance. | Tirzepatide | europepmc | 2026 |
| This observational study assessed outcomes in 8,127 women initiating GLP-1 receptor agonist therapy, primarily tirzepatide, through a digital program. Mean weight reduction was 16.1 kg, with 83.1% achieving ≥10% weight loss. Glycated hemoglobin decreased by 3.3 mmol/mol in participants with paired biomarker data. | Tirzepatide | PubMed | 2026 |
| Not reported in abstract. | Semaglutide | PubMed | 2026 |
| This review discusses the challenges and insights regarding pharmacotherapy for pediatric obesity, particularly focusing on GLP-1 receptor agonists like semaglutide. It emphasizes the need for pediatric clinical trials to verify the safety and efficacy of these medications. The paper highlights the historical context of weight-loss drugs and the current landscape of treatment options for adolescents. | Semaglutide | europepmc | 2026 |
| This study compared cardiovascular outcomes between tirzepatide and semaglutide in patients with type 2 diabetes (T2D). The analysis involved 271,685 patients in each group, focusing on the incidence of a composite of cardiovascular events and all-cause mortality. Tirzepatide was associated with lower incidences of these outcomes compared to semaglutide. | Semaglutide | europepmc | 2026 |
| This study evaluated 12-month weight loss outcomes comparing tirzepatide and sleeve gastrectomy (SG) in a diverse urban patient population. The SG group achieved a 30% total weight loss (TWL) and a 12 kg/m² BMI reduction, while the tirzepatide group had a 12% TWL and a 7 kg/m² BMI reduction. Statistically significant differences in weight loss were observed between the two cohorts (p < 0.001). | Semaglutide | europepmc | 2023 |
| This study evaluated weight nadirs and weight regain in adults with obesity or overweight and prediabetes during a 3-year treatment with tirzepatide. Participants who were tirzepatide-adherent and had at least a 5% weight reduction at nadir were analyzed. The mean weight regain from nadir to Week 176 was 3.8 kg, 4.4 kg, and 3.7 kg for tirzepatide doses of 5 mg, 10 mg, and 15 mg, respectively. | Tirzepatide | europepmc | 2026 |
| This study compared the metabolic effects of tirzepatide 15 mg and semaglutide 1 mg in patients with type 2 diabetes over 28 weeks. It was found that tirzepatide showed superior fasting glucose control primarily due to greater insulin-independent suppression of hepatic glucose production. The study utilized a mechanistic longitudinal model to analyze fasting measures. | Tirzepatide | PubMed | 2026 |
| This study estimated the treatment effect of tirzepatide on major adverse cardiovascular events (MACE) compared to an imputed placebo using data from SURPASS-CVOT and REWIND. The analysis included 2,055 participants from REWIND and all 13,165 participants from SURPASS-CVOT. The findings suggest a reduction in MACE and mortality outcomes associated with tirzepatide. | Tirzepatide | PubMed | 2026 |
| This study compared post-operative outcomes in patients undergoing primary total knee or hip arthroplasty who were prescribed tirzepatide versus semaglutide. The analysis involved a retrospective cohort of 8,797 patients with at least two prescriptions for either medication. At two years, tirzepatide was associated with lower odds of mechanical complications and periprosthetic joint infection compared to semaglutide. | Tirzepatide | biorxiv-preprint | 2026 |
| This study measured the effects of tirzepatide on hematopoietic stem and progenitor cells (HSPCs) and inflammatory monocytes in obese mice. The findings indicated that tirzepatide preserved blood lineages and HSPC cycling compared to caloric restriction at equal weight loss. Not reported in abstract. | Tirzepatide | biorxiv-preprint | 2026 |
| This review examines the impact of GLP-1 receptor agonists, specifically tirzepatide, on body weight and nutritional status. It reports mean body-weight reductions of 20.9% for tirzepatide and highlights a dietary intake reduction of 16–39%. Additionally, it discusses the associated risks of lean-body-mass loss and micronutrient deficiencies among users. | Tirzepatide | biorxiv-preprint | 2026 |
| This study measured weight loss in adults initiating compounded injectable tirzepatide at doses below 2.5 mg weekly. The population included individuals with a baseline BMI ≥27 kg/m2. Results indicated weight loss at various follow-up windows, with no therapeutic claims made. | Tirzepatide | biorxiv-preprint | 2026 |
| This study evaluated the association between semaglutide and suicidality in adults with overweight or obesity through a Bayesian meta-analysis of randomized trials. The primary outcome was completed suicide, with secondary outcomes including suicide attempts and suicidal ideation. The findings indicated no conclusive evidence of increased or decreased suicidality associated with semaglutide. | Semaglutide | biorxiv-preprint | 2026 |
| This study evaluated the efficacy of a lower dose of compounded semaglutide in conjunction with a behavioral weight management program over 16 weeks. Participants included users of Noom Weight, Noom Microdose GLP-1 Rx Program, and Noom GLP-1 Rx Program. Weight loss results showed NMGP users lost 8.3% and NGP users lost 8.6% of their baseline weight. | Semaglutide | biorxiv-preprint | 2026 |
| This study evaluated side effects of low versus standard doses of compounded semaglutide in a real-world setting over 16 weeks. It compared 7,682 users of the standard dose program to 2,877 users of the low dose program. The findings indicated lower odds of gastrointestinal and any side effects in the low dose group. | Semaglutide | biorxiv-preprint | 2026 |
| The study developed a near-infrared (NIR) light-triggered platform for on-demand drug release in bone repair using a multifunctional biomimetic scaffold. The scaffold demonstrated dual-mode release behavior, good biocompatibility, and high antibacterial activity. The system showed accelerated drug release upon NIR irradiation and sustained release over 28 days without it. | Tirzepatide | europepmc | 2026 |
| This study investigated risk factors for progression from type 2 diabetes mellitus (T2DM) to end-stage renal disease (ESRD) using Mendelian randomization and logistic regression analysis. The T2DM GWAS dataset included 433,540 individuals, while a clinical cohort of 875 patients was analyzed, with 140 patients (16%) progressing to ESRD. Elevated body mass index (BMI) was identified as a causal risk factor, while higher hematocrit was protective. | Semaglutide | europepmc | 2026 |
| This study assessed the feasibility and acceptability of the ZIP approach for patient-centered decision-making in lung cancer screening and blood pressure management. It involved 23 patients and 10 primary care physicians in a single center study. The ZIP discussions took less than 4 minutes on average. | Semaglutide | europepmc | 2026 |
| Not reported in abstract. | Tirzepatide | PubMed | 2026 |
| This study evaluated oral health outcomes in 184,582 users of semaglutide or tirzepatide over a 12-month period. The research found that 8.69% of GLP-1 users developed at least one new oral-health condition, with dry mouth being the most frequent at 5.29%. Compared to matched users of other anti-diabetic therapies, GLP-1 users had a lower incidence of various oral-health conditions. | Semaglutide | biorxiv-preprint | 2026 |
| The study evaluated the effects of oral semaglutide on the islets of Langerhans in a type 2 diabetes mellitus rat model. Forty male albino wistar rats were used, with a dose of 0.23 mg/kg/day administered for 21 days. Significant changes in islet morphology and cellular integrity were observed in the semaglutide-treated group compared to the diabetic control group. | Semaglutide | biorxiv-preprint | 2026 |
| This study examined patient heterogeneity in routine biomarkers among cohorts treated with dapagliflozin and/or semaglutide. It found that a one-dimensional physiological reserve score was not supported, leading to a two-class solution based on biomarkers. The findings suggest that these biomarkers may better capture patient heterogeneity than a single score. | Semaglutide | biorxiv-preprint | 2026 |
| This study analyzed the reporting of impaired gastric emptying associated with five glucagon-like peptide-1 receptor agonists (GLP-1 RAs) using the FDA Adverse Event Reporting System. Semaglutide exhibited the highest proportional reporting ratio (PRR) of 88.7 based on 3,052 reports. The study does not assert causation but highlights the reporting trends for these substances. | Semaglutide | biorxiv-preprint | 2026 |